Figure 2.
Mean ± SD visual analogue scale (VAS) alertness profiles for the moxonidine sustained release (SR) (•) and placebo (○) treatment groups during study day 8 and day 29. Each profile represents a different study day; measurements were performed from predose (first two data points) until 10 h postdose.
